# Concentra account plan

> Concentra is the largest US occupational health provider by locations, with FY2025 revenue of $2,163.4 million and about 13,000 colleagues and clinicians.

## At a glance

Concentra provides occupational health services in the United States: injury care for workers' compensation and employer services such as drug screens and physicals, through stand-alone centers, onsite clinics at employer worksites and Concentra Telemed. It serves about 200,000 employers, including 100% of the Fortune 100, and handled 13.5 million patient visits in 2025. FY2025 revenue was $2,163.4 million, up 13.9%, with net income of $172.8 million and Adjusted EBITDA of $431.9 million (20.0% margin). It has about 13,000 colleagues and affiliated physicians and clinicians and is completing its separation from Select Medical.

## Business units

- **Occupational health centers** (about 93% of FY2025 revenue): Stand-alone centers treating work injuries and providing employer services; 639 centers in 42 states at September 30, 2026. In Q3 2026 visits per day rose 4.9% to 58,312 and revenue per visit rose 3.3% to $152.14.
- **Onsite health clinics** (about 5% of FY2025 revenue): Clinics at employer worksites, 423 at September 30, 2026, expanded by the Pivot Onsite Innovations acquisition. Full-year 2025 revenue was $110.2 million (+72%); advanced primary care is expected to be a key growth driver.
- **Other businesses** (about 2% of FY2025 revenue): Includes Concentra Telemed; full-year 2025 revenue grew 8.7%.

## Strategic priorities

- **Organic visit and rate growth**: The long-term algorithm is low single digit visit growth, about 3% rate growth, and low single digits from M&A and de novos.
- **De novo openings**: 7 to 9 de novos targeted in 2026, with 15 new centers expected in 2026 overall and low double digit de novo openings in 2027; payback typically comes in under three years.
- **Bolt-on acquisitions**: Small deals of one to five centers, such as 4 centers acquired in Minnesota and the Reliant acquisition from MBI; no larger deals expected near term.
- **Onsite and new services**: Advanced primary care onsite, workers' compensation behavioral health via telemedicine, and adjacent areas such as workplace safety and specialty care; the onsite clinic market is estimated at about $17 billion.
- **Deleveraging and capital returns**: A 2.5x leverage target, debt paydown and a new $250 million buyback programme authorised on November 4, 2026.

## Latest results

In Q3 2026 revenue was $622.1 million, up 8.6%, driven mainly by organic growth in visit volume and revenue per visit; net income was $67.8 million against $49.8 million and Adjusted EBITDA $140.2 million (22.5% margin). Employer services visits rose 5.8%, helped by hiring-related drug screens and physicals in transportation, logistics, manufacturing and construction. Nine-month revenue was $1,797.7 million (+10.7%). 2026 guidance was raised to revenue of $2.36-2.38 billion and Adjusted EBITDA of $505-510 million, with free cash flow guidance kept at $220-240 million.

## Investments and deals

- **Nova Medical Centers**: 67 centers acquired in March 2025 for $265.0 million.
- **Pivot Onsite Innovations**: Over 240 onsite clinics acquired in June 2025 for $54.4 million.
- **New centers in 2026**: 7 centers acquired and 5 de novos opened in the first nine months of 2026, with de novos in Kansas City, Boise and Daytona Beach.
- **Debt paydown and buybacks**: A $50.0 million voluntary term loan prepayment in Q3 2026; 2.1 million shares repurchased for $60.6 million in nine months.

## Challenges and risks

- **State fee schedules**: State workers' compensation fee schedules and cost containment drive rates; Concentra has no centers in New York because of its low fee schedule.
- **Labour costs**: Labour shortages and wage costs are stated risks; wage inflation is about 3%.
- **Indebtedness**: A $942.9 million term loan and $650.0 million senior notes at year-end 2025; the leverage ratio was 2.90x at September 30, 2026 against a 2.5x target.
- **Separation from Select Medical**: Standalone public-company and separation costs raised G&A to 9.8% of revenue in Q3 2026; the transition services agreement ends at the end of November.

## What leadership says

> "enters in this next chapter from a position of considerable strength" — Keith Newton, Executive Chairman, Q3 2026 earnings call, 2026-11-06

> "favorable labor market conditions in many of the blue collar sectors we serve, and continued market share gains" — Matthew T. DiCanio, President and Chief Executive Officer, Q3 2026 earnings call, 2026-11-06

> "specialized clinical approach and fully integrated medical model" — Keith Newton, Chief Executive Officer, Q4 2025 earnings call, 2026-02-27


## Where a supplier can help

- **Clinic build-out and fit-out**: The de novo programme and bolt-on acquisitions need real estate, construction, medical equipment and IT set-up partners.
- **Clinical staffing and workforce tools**: Labour shortages and wage costs make staffing, scheduling and retention solutions relevant to the cost of services gains.
- **Standalone back-office systems**: The end of the Select Medical transition services agreement creates needs for finance, HR and IT systems and services.
- **Sales and account management technology**: Sales teams use new technology and AI to spot customers at risk of churn; CRM, analytics and AI vendors fit the organic growth priority.
- **Onsite and telehealth services**: Advanced primary care and behavioral health via telemedicine call for telehealth platforms and clinical partners.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Concentra Group Holdings Parent, Inc. Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/2014596/000201459626000029/cghp-20251231.htm)

Annual report · 2026-02-26

- Concentra is the largest provider of occupational health services in the United States by number of locations: 628 stand-alone occupational health centers in 41 states and 411 onsite health clinics at employer worksites in 44 states at December 31, 2025, plus Concentra Telemed; services in 47 states and the District of Columbia.
- FY2025 revenue was $2,163.4 million, up 13.9% from $1,900.2 million; net income $172.8 million; Adjusted EBITDA $431.9 million (20.0% margin, vs 19.8% in 2024).
- Revenue mix: occupational health centers about 93%, onsite health clinics about 5%, other businesses about 2%. By payor, 60.9% came from workers' compensation carriers, TPAs and self-insured employers and 37.6% from employers and employer-services TPAs.
- Customer base: about 200,000 employers including 100% of the Fortune 100, about 375,000 employer locations; the top 1,000 employers account for about 37% of occupational health center revenue and no industry exceeds 10% of the business.
- Volume and price: 13.5 million patient visits in 2025 (53,124 visits per day, up 7.7%); revenue per visit up 4.3% to $147.42; about 839,000 initial injury visits, roughly one in four US work-related injuries.
- 2025 was an acquisition year: Nova Medical Centers (67 centers, $265.0 million) in March and Pivot Onsite Innovations (over 240 onsite clinics, $54.4 million) in June; 7 de novo centers opened.
- Growth strategy: organic share gains plus about 3% annual rate growth, acquisitions and de novos, new services (advanced primary care onsite, workers' compensation behavioral health via telemedicine) and adjacent areas such as workplace safety and specialty care; estimated onsite clinic market of about $17 billion.
- Balance sheet: $942.9 million term loan and $650.0 million senior notes, leverage ratio 3.4x; a $100 million buyback programme authorised in November 2025 and a quarterly dividend of $0.0625 per share.
- Key risks: state workers' compensation fee schedules and cost containment, labour shortages and wage costs, competition, substantial indebtedness, corporate-practice-of-medicine rules, and completing the separation from Select Medical (transition services agreement).
- About 13,000 colleagues and affiliated physicians and clinicians; CEO William K. Newton and President & CFO Matthew T. DiCanio at the filing date.

### [Concentra Group Holdings Parent, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/2014596/000201459626000077/cghp-20260930.htm)

Interim report · 2026-11-05

- Q3 2026 revenue was $622.1 million, up 8.6% from $572.8 million, driven mainly by organic growth in both visit volume and revenue per visit; nine-month revenue was $1,797.7 million (+10.7%).
- Q3 net income was $67.8 million (10.9% of revenue) against $49.8 million; Adjusted EBITDA was $140.2 million (22.5% margin) against $118.9 million (20.8%).
- Occupational health center visits per day rose 4.9% to 58,312: workers' compensation 26,407 (+4.2%) and employer services 31,126 (+5.8%). Revenue per visit rose 3.3% to $152.14.
- Footprint at September 30, 2026: 639 occupational health centers in 42 states and 423 onsite health clinics; 7 centers acquired and 5 de novos opened in the first nine months.
- Cost of services fell to 68.6% of revenue from 70.8% thanks to staffing efficiencies; G&A rose to 9.8% of revenue, partly because of standalone public-company and separation costs.
- Debt reduction: a $50.0 million voluntary term loan prepayment in Q3; leverage ratio 2.90x; no revolver drawings.
- Capital returns: 2.1 million shares repurchased for $60.6 million in nine months, including 1.0 million shares bought from chairman Robert A. Ortenzio for $34.65 million; a new $250 million buyback programme authorised on November 4, 2026; quarterly dividend kept at $0.0625.

### [Concentra (CON) Q3 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/11/06/concentra-con-q3-2026-earnings-call-transcript/)

Executive talk · Matthew T. DiCanio, President and Chief Executive Officer · 2026-11-06

- First call after the November 1, 2026 leadership change: Matthew T. DiCanio became CEO, Tanner Newton CFO and Keith Newton executive chairman. Keith Newton said Concentra "enters in this next chapter from a position of considerable strength".
- Q3 2026: revenue $622.1 million (+8.6%), net income $67.8 million (+36%), Adjusted EBITDA $140.2 million (+17.9%), margin 22.5% (+178 bp).
- Visits per day rose 4.9% to more than 58 thousand. DiCanio attributes this to favorable labour markets in blue-collar sectors and market share gains, with growth broad based across all 6 regions. Customer retention is "at multiyear highs".
- Employer services visits rose 5.8%, with hiring-related drug screens and physicals up in transportation, logistics, manufacturing and construction. Management reads this as a leading indicator of workers' comp volumes.
- Footprint: 4 centers acquired in Minnesota, de novos in Kansas City, Boise and Daytona Beach; 15 new centers expected in 2026 and "low double digit de novo openings in 2027". A New York entry is being explored if the state's fee schedule rises.
- Raised 2026 guidance: revenue $2.36-2.38 billion, Adjusted EBITDA $505-510 million; free cash flow guidance kept at $220-240 million.
- Capital allocation: growth first, a 2.5x leverage target, and buybacks raised alongside debt paydown under a new $250 million authorization. Separation from Select Medical ends with the TSA at the end of November.
- Data centers are a growing but "relatively small and immaterial" part of the business; the company is tracking more than 300 projects. Wage inflation is about 3%.

### [Concentra (CON) Q4 2025 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/02/27/concentra-con-q4-2025-earnings-call-transcript/)

Executive talk · Keith Newton, Chief Executive Officer · 2026-02-27

- Full-year 2025: revenue $2.2 billion (+13.9%), $2.0 billion excluding Nova and Pivot (+6.4%); Adjusted EBITDA $431.9 million (+14.6%), margin 20.0%; free cash flow $197.8 million, conversion 114%.
- Q4 2025 revenue was $539.1 million (+15.9%) and visits per day rose 9% to more than 51,000 (+2.6% excluding Nova).
- New claim studies covering more than 550,000 claims from 2020 to 2025 show 25% lower total claim cost and 65 fewer days per claim for Concentra-treated workers.
- Onsite segment: Q4 revenue $36.2 million (+112%), with 14.6% organic growth; full-year $110.2 million. Advanced primary care is expected to be "a key growth driver".
- Initial 2026 guidance: revenue $2.25-2.35 billion, Adjusted EBITDA $450-470 million, free cash flow $200-225 million, capex $70-80 million, leverage about 3.0x at year-end.
- Growth plan: 7 to 9 de novos targeted in 2026 ("a record"), potentially double-digit sites in 2027, and small 1-5 center bolt-ons such as the Reliant acquisition from MBI. No larger deals are expected near term.
- New York could support "dozens of locations or more" if its workers' comp fee schedule rises enough. A proposed roughly 50% E&M increase is "a good first step" but not yet enough.
- Separation from Select: more than 80% of FTEs hired, with TSA costs expected to fall close to zero by mid-2026. Sales teams are using new technology and AI to spot customers at risk of churn.

## Questions about Concentra

### What does Concentra do?

Concentra provides occupational health services in the United States, treating work injuries for workers' compensation and providing employer services such as drug screens and physicals through centers, onsite clinics and telemedicine.

### What is Concentra's revenue?

FY2025 revenue was $2,163.4 million, up 13.9%. 2026 guidance is revenue of $2.36-2.38 billion.

### How many employees does Concentra have?

About 13,000 colleagues and affiliated physicians and clinicians.

### Who leads Concentra?

Since November 1, 2026, Matthew T. DiCanio is CEO, Tanner Newton CFO and Keith Newton executive chairman.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
